BOSTON, Feb. 05, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced it will participate in multiple panel discussions at the 4th Annual Bloomberg Intelligence Healthcare Event on Friday, Feb. 12. The panels will begin at 1:30 pm ET and focus on the evolving strategies for biosimilars, as well as provide legal and regulatory updates on biosimilars.
The conference will be held on Friday, Feb. 12 starting at 8:30 am ET in New York City. Additional information is available at http://b.bloomberg.com/BIHealthCare-regsa. The link to the live audio webcast and replay of the presentation will be available through Bloomberg terminals at Live <go>.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS’ goal is to improve global patient access to important, cost-effective medicines. EPIRUS' current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®); BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)i. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets. For more information visit EPIRUS’ website at www.epirusbiopharma.com.
i Remicade is a registered trademark of Johnson and Johnson (www.jnj.com); Humira is a registered trademark of AbbVie (www.abbvie.com); Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group (www.gene.com); Stelara is owned and marketed by Centocor Ortho Biotech Inc, a wholly owned subsidiary of Johnson and Johnson (www.jnj.com); Simponi is marketed by Janssen Biotech Inc (www.janssenbiotech.com); Soliris is a registered trademark of Alexion Pharmaceuticals, Inc. (www.alxn.com)
Contact Information:
For media inquiries:
Hope Buggey, FleishmanHillard
+1-919-336-3786
hope.buggey@fleishman.com
For investor inquiries:
Marek Ciszewski, J.D., EPIRUS Biopharmaceuticals
+1-617-553-9716
mciszewski@epirusbiopharma.com
